Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 57.23 Billion |
| USD 117.43 Billion | |
| % | |
|
Global Blood Cancer Market Segmentation, By Type (Leukaemia, Lymphoma, Myeloma), Treatment (Medication, Radiation Therapy, Stem Cell Transplant, Others), Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
According to a survey by Bristol-Myers Squibb, approximately 1.85 million new cases of blood cancer will be diagnosed worldwide in 2040, with 918,872 cases of lymphoma, 656,345 cases of leukaemia, and 275,047 cases of myeloma. Furthermore, the survey predicted that by 2040, there will be around 1,100,000 fatalities worldwide owing to blood cancer. Cancer that starts in blood-forming tissue, such as bone marrow, or in immune system cells. Leukemia, lymphoma, and multiple myeloma are examples of blood cancers. Hematologic cancer is another name for it. Drugs including bosulif, busulfan, bosutinib and busulfex are used to treat blood cancer.
Global blood cancer market size was valued at USD 57.23 billion in 2024 and is projected to reach USD 117.43 billion by 2032, with a CAGR of 9.40% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
|
Attributes
|
Blood Cancer Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Blood Cancer Market Definition
Most blood cancers, also known as hematologic malignancies, begin in the bone marrow, which produces blood. When aberrant blood cells develop out of control, they disrupt the function of normal blood cells, which fight infection and make new blood cells. Commercially available chemotherapeutic drugs for the treatment of blood cancer include Leukeran, Oncotrex, Cytarine, Neosar, Gleevec, and others. Anticancer medicines are used in chemotherapy which functions by inhibiting the growth of cancer cells in the body. Chemotherapy for blood cancer may include administering numerous medications in a specific order. This treatment can also be used in conjunction with a stem cell transplant. Radiation therapy can be used to fight cancer as well as relieve pain and discomfort.
Blood Cancer Market Dynamics
Drivers
The expansion of the blood cancer market is fueled by the increasing use of microRNA treatments, the rise of nanomedicine platforms, and the constant introduction of effective and safe therapeutics. With the addition of monoclonal antibodies and histone deacetylase (HDAC) inhibitors to the present therapies array, the medicines market is likely to gain traction. Because of the established clinical profile, clinicians favour biologic therapy with monoclonal antibodies such as darzalex and empliciti.
The rising prevalence of blood cancer is estimated to enhance the blood cancer market's growth rate. Blood cancer is a form of hematological cancer triggered by certain genetic defects. The disease is treated with medications that modify the immune system and assist in improving the efficacy of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusions.
Another significant factor influencing the growth rate of blood cancer market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising geriatric population and increasing number of obese population will expand the blood cancer market.
Opportunities
The blood cancer market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the blood cancer market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. The introduction of monoclonal antibodies (mAbs) (including Empliciti and Darzalex) will act as major opportunity for market's growth, as they will not only provide a new therapeutic option for blood cancer patients, but they will also extend the time between relapses, extending the duration of Revlimid and Velcade therapies. Ninlaro and Kyprolis, two second-generation proteasome inhibitors, will also be available to these patients, expanding their therapy options. This will have an impact on the industry and market, which is now controlled by Revlimid, an immunomodulator, and Velcade, a proteasome inhibitor.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the blood cancer market growth during the forecast period.
Restraints/Challenges
On the other hand, low treatment rates in developing countries because of the high cost associated with the treatment of blood cancer will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the blood cancer market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2025-2032.
This blood cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blood cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Blood cancer market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
The blood cancer market is segmented on the basis of type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
Treatment
Diagnosis
Dosage Forms
Route of Administration
End-Users
Distribution Channel
The blood cancer market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel as referenced above.
The countries covered in the blood cancer market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the blood cancer market because of the growing prevalence of blood cancer and the rising geriatric population. Additionally, growing demand for biologic therapies and people's unhealthy lifestyle will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing penetration of novel cancer drugs and rising healthcare expenditure. Also, growing government initiatives will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The blood cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blood cancer market.
Blood Cancer Market Leaders Operating in the Market Are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.